ArticleIJID regions2026
Prevalence and epidemiology of hepatitis C in Uzbekistan: results from a population-based serosurvey, 2022.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Uzbekistan launched a national viral hepatitis elimination program in 2022, but precise estimates of hepatitis C prevalence are needed to guide elimination efforts. In 2022, we conducted a cross-sectional population-based seroprevalence survey among adults (aged ≥18 years) and children (aged 5-17 years) in Uzbekistan to estimate the prevalence and epidemiology of hepatitis C. Methods: Interviewers collected information on demographics and potential exposures to hepatitis C virus (HCV). Blood samples were tested for HCV antibodies (anti-HCV) and, if positive, for HCV RNA. We calculated weighted prevalence estimates and 95% confidence intervals (CIs) and assessed factors associated with HCV exposure and infection using multivariable logistic regression. Results: Overall, 9066 adults and 4087 children were tested for hepatitis C. The prevalence of anti-HCV and HCV RNA among adults was 3.9% (95% CI: 3.3-4.6) and 2.0% (95% CI: 1.6-2.6), respectively, and among children was 1.1% (95% CI: 0.5-2.2) and 0.5% (95% CI: 0.2-1.0), respectively. Prevalence of anti-HCV and HCV RNA increased with age. Ever having surgery or an invasive medical procedure (adjusted odds ratio [aOR] 1.65 [95% CI: 1.09-2.50]), and past incarceration (aOR 4.88 [95% CI: 1.46-16.29]) were associated with HCV exposure, whereas a history of invasive dental procedures (aOR 2.63 [95% CI: 1.11-6.22]) and receipt of a tattoo (aOR 3.84 [95% CI: 1.57-9.38]) were associated with chronic infection. Conclusion: Uzbekistan could consider nationwide HCV screening, focusing first on older age groups and incarcerated persons, and implementing infection prevention and control measures in health care settings to help prevent future infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.